1.Seropositivity of anti-HBs titer among college students several years after completion of the primary hepatitis B vaccination series
Monique P. Valerio-Fabros ; Jay Ron O. Padua
Pediatric Infectious Disease Society of the Philippines Journal 2024;25(2):11-21
BACKGROUND
The Philippines is hyperendemic for hepatitis B infection. Vaccination is crucial for protection. Local data on the antibody response after completion of the primary vaccination series is limited.
OBJECTIVEThis study aimed to measure the anti-HBs levels among college students who completed primary hepatitis B vaccination series, compare seropositivity across stratified groups and correlate anti-HBs levels with the time elapsed since the last vaccine dose.
METHODSThis cross-sectional study included 111 college students in health-related courses with immunization record showing the complete primary Hepatitis B vaccination series. Participants were stratified based on the following vaccination schedules: 0-1-6-month group; 0-1-2-month group; and booster group. Anti-HBs titers were determined.
DATA ANALYSISStatistical analyses included One-way ANOVA, Kruskal-Wallis test, Fisher’s Exact test and Shapiro-Wilk normality test. Kaplan-Meier Survival Estimate assessed the probability of anti-HBs seropositivity over time. Data were analyzed using STATA 13.1.
RESULTSThe baseline characteristics of the study population were homogenous. The median anti-HBs titer several years after primary vaccination was low at 2.9 mIU/mL. Participants in the booster group had the highest seropositivity rate (57.14%) with a median titer of 30.16 mIU/mL. There was an inverse relationship between anti-HBs titer and elapsed time since the last vaccine dose. Kaplan-Meier Survival Estimate showed that the seropositivity decreases to 90.56% after 15.8 years, 51.3% after 17.5 years, and 2.97% at 18 years.
CONCLUSIONThis study revealed low anti-HBs titers among students who previously completed primary vaccination series, with no significant difference between two schedules. Booster doses resulted in the highest seropositivity. Over-all, seropositivity declines over time.
Hepatitis B ; Hepatitis B Antibodies
3.Hepatitis B Virus-Associated Nephropathy.
Korean Journal of Nephrology 2000;19(6):987-988
No abstract available.
Hepatitis B*
;
Hepatitis*
4.Expression and Characterization of Chimeric Antigens of Hepatitis B and D Viruses : Implications for the Development of Divalent Vaccine.
Dong Hwa CHOI ; Jung Min PARK ; Kyu Jin PARK ; Soon Bong HWANG ; Soo Ho CHOI
Journal of Bacteriology and Virology 2001;31(4):361-367
No abstract available.
Hepatitis B*
;
Hepatitis*
5.Characteristics of Hepatitis B Virus(HBV) and HBV DNA Quantitative Tests.
Korean Journal of Clinical Microbiology 2003;6(2):89-96
No abstract available.
DNA*
;
Hepatitis B*
;
Hepatitis*
6.Preventin of Hepatitis B.
Journal of the Korean Pediatric Society 1983;26(5):421-427
No abstract available.
Hepatitis B*
;
Hepatitis*
7.Vectical Transmission of Hepatitis B.
Journal of the Korean Pediatric Society 1983;26(5):412-412
No abstract available.
Hepatitis B*
;
Hepatitis*
8.Antiviral Therapy Hepatitis B in Renal Transplant Recipients.
Korean Journal of Nephrology 2006;25(6):877-885
No Abstract available.
Hepatitis B*
;
Hepatitis*
;
Transplantation*
9.Anti-viral Treatment in Chronic Viral Hepatitis B.
Journal of the Korean Academy of Family Medicine 2003;24(6):503-509
No abstract available.
Hepatitis B*
;
Hepatitis*
10.A comparative study on the efficacy of low-dose intradermal hepatitis B vaccination.
Journal of the Korean Academy of Family Medicine 1992;13(1):28-34
No abstract available.
Hepatitis B*
;
Hepatitis*
;
Vaccination*
Result Analysis
Print
Save
E-mail